S. J. Lichtenstein

发表

Computerized histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas.

R. Greenberg, J. Gamel, I. McLean, 1982, Human pathology.

Use of photoscreening for children's vision screening.

George S. Ellis, Jack Swanson, Jay Bernstein, 2002, Pediatrics.

Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: Clinical implications and a review of kinetics of kill studies

S. J. Lichtenstein, D. Stroman, R. Wagner, 2007, Advances in therapy.

Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.

S. Levy, S. J. Lichtenstein, B. Marshall, 2012, Journal of pediatric ophthalmology and strabismus.

Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.

S. J. Lichtenstein, M. Rinehart, 2003, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin

R. D. Gross, S. J. Lichtenstein, D. Granet, 2010, Clinical ophthalmology.

An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite®

S. J. Lichtenstein, D. Granet, James A Katz, 2007, Clinical ophthalmology.

Pharmacology, clinical efficacy and safety of olopatadine hydrochloride

S. J. Lichtenstein, M. Abelson, 2006, Expert review of clinical immunology.

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis

R. D. Gross, S. J. Lichtenstein, S. Robertson, 2007, Advances in therapy.

Safety and tolerability of olopatadine 0.2% in children and adolescents.

R. D. Gross, S. J. Lichtenstein, S. Robertson, 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.

I. Schwab, S. J. Lichtenstein, J. McCulley, 2003, Ophthalmology.

Peripheral retinal nonperfusion in septo-optic dysplasia (de Morsier syndrome).

J. Keenan, N. Smaoui, S. J. Lichtenstein, 2011, Archives of ophthalmology.

Effects of fuchsin variants in aldehyde fuchsin staining.

S. J. Lichtenstein, G. Nettleton, 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Reactivation of retinopathy of prematurity after bevacizumab injection.

S. J. Lichtenstein, M. Shapiro, M. Blair, 2012, Archives of ophthalmology.

Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients

S. J. Lichtenstein, M. Rinehart, 2004 .

Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.

S. J. Lichtenstein, M. Shapiro, M. Blair, 2013, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.

Ravi D. Patel, S. J. Lichtenstein, M. Shapiro, 2012, Archives of ophthalmology.

Fluoroquinolones compared to 1% azithromycin in DuraSite® for bacterial conjunctivitis

S. J. Lichtenstein, D. Granet, 2008, Clinical ophthalmology.

Fluoroquinolones compared to 1% azithromycin in DuraSite® for bacterial conjunctivitis

S. J. Lichtenstein, D. Granet, 2008, Clinical ophthalmology.

Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.

S. J. Lichtenstein, M. Shapiro, M. Blair, 2013, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.